Your session is about to expire
← Back to Search
Procedure
Surgical Techniques for Crohn's Disease (SPARES Trial)
N/A
Recruiting
Led By Amy Lightner, MD
Research Sponsored by The Cleveland Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Males and females 18-65 years of age.
Medically refractory disease or inability to tolerate ongoing medical therapy
Must not have
Emergent indication for an operation
Patients who are undergoing an ileal resection only (NOT ileocecal) because the disease spares the distal most aspect of ileum and ileocecal valve
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 and 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial will compare two operative techniques for patients with Crohn's disease who are undergoing a primary ileocecal resection. The primary endpoint is 6-month endoscopic recurrence.
Who is the study for?
Adults aged 18-65 with Crohn's Disease affecting less than 30 cm of the terminal ileum and not responding to standard treatments can join. They must be able to follow the study protocol for 5 years and give consent. Excluded are those with a history of cancer, other significant medical conditions, or requiring additional surgeries beyond ileocolic resection.
What is being tested?
The SPARES trial is testing two surgical methods in Crohn's patients: high ligation versus mesenteric sparing of the ileocolic artery during resection. It aims to see which technique better prevents disease recurrence after surgery, monitored over six months to five years.
What are the potential side effects?
Potential side effects aren't specified but may include typical risks associated with abdominal surgery such as infection, bleeding, pain at incision site, bowel obstruction due to scar tissue formation (adhesions), and complications from anesthesia.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 18 and 65 years old.
Select...
My condition hasn't improved with current treatment or I can't tolerate it.
Select...
My Crohn's disease affects less than 30 cm of my ileocolic region.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I need surgery urgently.
Select...
I am having surgery to remove part of my small intestine, but not the valve connecting it to the large intestine.
Select...
I am having a second surgery to remove part of my small intestine and colon.
Select...
I need more than just ileocolic resection surgery due to additional disease locations.
Select...
My surgery included creating a temporary opening for waste (ileostomy).
Select...
I have more than 30 cm of disease in the last part of my small intestine.
Select...
I am under 18 years old.
Select...
I have a history of autoimmune diseases, but not Crohn's disease.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 and 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 and 5 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Endoscopic recurrence based on Rutgeert scoring at the time of colonoscopy
Secondary study objectives
Clinical Recurrence - Crohn's Disease Activity Index (CDAI)
Endoscopic Recurrence - Rutgeert score
Surgical Recurrence
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Active Control
Group I: mesenteric sparing for a primary ileocolic resectionActive Control2 Interventions
Randomized control trial of two operative techniques Operative approach of a high ligation of ileocolic artery as compared to mesenteric sparing for a primary ileocolic resection
Group II: high ligation of ileocolic arteryActive Control2 Interventions
Randomized control trial of two operative techniques Operative approach of a high ligation of ileocolic artery as compared to mesenteric sparing for a primary ileocolic resection
Find a Location
Who is running the clinical trial?
The Cleveland ClinicLead Sponsor
1,051 Previous Clinical Trials
1,370,711 Total Patients Enrolled
Amy Lightner, MD2.33 ReviewsPrincipal Investigator - The Cleveland Clinic
The Cleveland Clinic
18 Previous Clinical Trials
1,362 Total Patients Enrolled
5Patient Review
Dr. Lightner's excellent skillset saved my husband's life. We are incredibly grateful to her.
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have had cancer before, but not melanoma or any non-localized skin cancers.I need surgery urgently.I haven't had major heart issues or other serious health problems in the last 6 months.I am between 18 and 65 years old.My condition hasn't improved with current treatment or I can't tolerate it.I am having surgery to remove part of my small intestine, but not the valve connecting it to the large intestine.My Crohn's disease affects less than 30 cm of my ileocolic region.I am having a second surgery to remove part of my small intestine and colon.I need more than just ileocolic resection surgery due to additional disease locations.My surgery included creating a temporary opening for waste (ileostomy).I am capable of understanding and signing the consent form.I have more than 30 cm of disease in the last part of my small intestine.I am under 18 years old.I am currently taking medications like corticosteroids or antibiotics.I have a history of autoimmune diseases, but not Crohn's disease.
Research Study Groups:
This trial has the following groups:- Group 1: mesenteric sparing for a primary ileocolic resection
- Group 2: high ligation of ileocolic artery
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger